Table 1. Incidence and severity of EAP... | American Society of Hematology

Table 1.

Incidence and severity of EAP in d3tx B6AF1 mice that received different numbers of Tregs from donors with or without prostates

			EAP in d3tx recipients
Treg donor	Treg donor treatment (duration)	Treg nos.	Incidence, % (no.)	Severity^*
None	–	–	53 (17)	2.3 ± 0.2
Male 1	–	3 × 10⁴	56 (9)	1.9 ± 0.4
Male 2	–	1 × 10⁵	37 (8)	1.8 ± 0.6
Male 3	–	3 × 10⁵	0 (14)	–
Female 1	–	3 × 10⁴	67 (12)	2.2 ± 0.3
Female 2	–	1 × 10⁵	67 (12)	2.4 ± 0.3
Female 3	–	3 × 10⁵	26 (23)	1.6 ± 0.2
Female 4	–	1 × 10⁶	0 (5)	–
Male 4	NOr	3 × 10⁵	45 (11)	1.9 ± 0.5
Male 5	NOr	1 × 10⁶	0 (16)	–
Male 6	NOr-DHT (6 wk)	3 × 10⁵	11 (9)	0.5 ± 0
Male 7	NOr-DHT (2 wk)	3 × 10⁵	6 (16)	2.0 ± 0
Male 8	NOr-DHT (1 wk)	3 × 10⁵	24 (21)	1.6 ± 0.4
Male 9	NOr-ATx-DHT†	3 × 10⁵	0 (20)	–
Female 5	DHT-prostate‡	3 × 10⁵	8 (12)	2.0 ± 0
Female 6	DHT‡	3 × 10⁵	58 (12)	1.8 ± 0.3
Female 7	Prostate‡	3 × 10⁵	30 (10)	2.0 ± 0.6

			EAP in d3tx recipients
Treg donor	Treg donor treatment (duration)	Treg nos.	Incidence, % (no.)	Severity^*
None	–	–	53 (17)	2.3 ± 0.2
Male 1	–	3 × 10⁴	56 (9)	1.9 ± 0.4
Male 2	–	1 × 10⁵	37 (8)	1.8 ± 0.6
Male 3	–	3 × 10⁵	0 (14)	–
Female 1	–	3 × 10⁴	67 (12)	2.2 ± 0.3
Female 2	–	1 × 10⁵	67 (12)	2.4 ± 0.3
Female 3	–	3 × 10⁵	26 (23)	1.6 ± 0.2
Female 4	–	1 × 10⁶	0 (5)	–
Male 4	NOr	3 × 10⁵	45 (11)	1.9 ± 0.5
Male 5	NOr	1 × 10⁶	0 (16)	–
Male 6	NOr-DHT (6 wk)	3 × 10⁵	11 (9)	0.5 ± 0
Male 7	NOr-DHT (2 wk)	3 × 10⁵	6 (16)	2.0 ± 0
Male 8	NOr-DHT (1 wk)	3 × 10⁵	24 (21)	1.6 ± 0.4
Male 9	NOr-ATx-DHT†	3 × 10⁵	0 (20)	–
Female 5	DHT-prostate‡	3 × 10⁵	8 (12)	2.0 ± 0
Female 6	DHT‡	3 × 10⁵	58 (12)	1.8 ± 0.3
Female 7	Prostate‡	3 × 10⁵	30 (10)	2.0 ± 0.6

– indicate none.

Mean ± SD of mice with disease

Six-week-old NOr males were thymectomized and received implants of DHT pellets for 2 weeks

Six-week-old females received implants of prostate or DHT pellet or both for 2 weeks